EUCRU has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
EUCRU has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Eucrates Biomedical Acquisition's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2022 was $. Eucrates Biomedical Acquisition's 10-Year median PS Ratio is . Therefore, the Median PS Value for today is $0.00.
As of today (2024-12-15), Eucrates Biomedical Acquisition's share price is $10.02. Eucrates Biomedical Acquisition's Median PS Value is $0.00. Therefore, Eucrates Biomedical Acquisition's Price to Median PS Value for today is 0.00.
The historical rank and industry rank for Eucrates Biomedical Acquisition's Median PS Value or its related term are showing as below:
The historical data trend for Eucrates Biomedical Acquisition's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eucrates Biomedical Acquisition Annual Data | |||||||
Trend | Dec20 | Dec21 | Dec22 | ||||
Median PS Value | - | - | - |
Eucrates Biomedical Acquisition Quarterly Data | ||||||||||
Aug20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | |
Median PS Value | Get a 7-Day Free Trial | - | - | - | - | - |
For the Shell Companies subindustry, Eucrates Biomedical Acquisition's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Diversified Financial Services industry and Financial Services sector, Eucrates Biomedical Acquisition's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Eucrates Biomedical Acquisition's Price-to-Median-PS-Value falls into.
Eucrates Biomedical Acquisition's Median PS Value for today is calculated as
Median PS Value | = | Revenue per Share (TTM) | * | 10-Year Median PS Ratio |
= | * | |||
= | 0.00 |
10-Year Median PS Ratio is .
Eucrates Biomedical Acquisition's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eucrates Biomedical Acquisition (NAS:EUCRU) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Eucrates Biomedical Acquisition's Price to Median PS Value for today is calculated as
Price to Median PS Value | = | Share Price | / | Median PS Value |
= | 10.02 | / | 0.00 | |
= |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Eucrates Biomedical Acquisition's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Stelios Papadopoulos | director, 10 percent owner | 3 SOMERSET DRIVE SOUTH, GREAT NECK NY 11020 |
William I Campbell | director | 270 PARK AVENUE, NEW YORK NY 10017 |
Nina B. Shapiro | director | 2201 WALNUT AVENUE, SUITE 100, FREMONT CA 94538 |
Parag Saxena | director, 10 percent owner, officer: Chief Executive Officer | 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019 |
Daphne Karydas | director | 35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3, WALTHAM MA 02451 |
Atanuu Agarrwal | officer: Vice President | 250 WEST 55TH STREET, NEW YORK NY 10019 |
Gonzalo Cordova | officer: Chief Financial Officer | 250 WEST 55TH STREET, NEW YORK NY 10019 |
Eucrates Llc | 10 percent owner | 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019 |
Shrikant Sathe | officer: Senior Vice President | C/O EUCRATES LLC, 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019 |
Evangelos Vergetis | director, officer: President, COO | C/O EUCRATES LLC, 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019 |
Amitabh Singhal | director | C/O EUCRATES LLC, 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019 |
From GuruFocus
By PRNewswire PRNewswire • 06-01-2021
By PRNewswire PRNewswire • 04-11-2023
By PRNewswire PRNewswire • 10-28-2020
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.